Quantiferon TB gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents

Clinical and Experimental Rheumatology

Volumn 31, Issue 1, 2013, Pages 111-117

  Klein, Martin ^a   Jarošová, Kateřina ^a   Forejtová, Šásrka ^a   Bečvář, Radim ^a   Šedová, Liliana ^a   Pavelka, Karel ^a   Šimková, Gabriela ^a   Svobodová, Radka ^a   Hviščová, Katarína ^a   Mann, Heřman ^a   Půtová, Ivana ^a   Vencovský, Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Arthritis; Ifn ; TNF inhibition; Tuberculosis

Indexed keywords

ADALIMUMAB; ETANERCEPT; GAMMA INTERFERON; GLUCOCORTICOID; INFLIXIMAB; MYCOBACTERIUM ANTIGEN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERFERON PRODUCTION; INTERMETHOD COMPARISON; JUVENILE RHEUMATOID ARTHRITIS; LATENT TUBERCULOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TUBERCULIN TEST;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874866144     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. DIXON WG, HYRICH KL, WATSON KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
2. TUBACH F, SALMON D, RAVAUD P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-94.
3. WOLFE F, MICHAUD K, ANDERSON J, URBANSKY K Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-9.
4. KEANE J, GERSHON S, WISE RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
5. CAGATAY T, AYDIN M, SUNMEZ S et al. Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int 2010; 30: 1459-638.
6. GÓMEZ-REINO JJ, CARMONA L, ANGEL DESCALZO M; BIOBADASER GROUP Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7.
7. GÓMEZ-REINO JJ, CARMONA L, ANGEL DESCALZO M et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-61.
8. VAN BESOUW NM, VAN DER MAST BJ, VAN DE WETERING J, RISCHEN-VOS J, WEIMAR W Tapering immunosuppressive therapy significantly improves in vivo cutaneous delayed type hypersensitivity responses. Transpl Immunol 2008; 19: 229-34.
9. SOBORG B, RUHWALD M, HETLAND ML et al. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 2009; 36: 1876-84.
10. PONCE DE LEÓN D, ACEVEDO-VÁSQUEZ E, SÁNCHEZ-TORRES A et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1.
11. BOCCHINO M, MATARESE A, BELLOFIORE B et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008; 27: 907-13.
12. SHOVMAN O, ANOUK M, VINNITSKY N et al. QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis 2009; 13: 1427-32.
13. LALVANI A, MILLINGTON KA Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008; 8: 147-52.
14. PARK JH, SEO GY, LEE JS, KIM TH, YOO DH Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009; 36: 2158-63.
15. TISSOT F, ZANETTI G, FRANCIOLI P, ZELLWEGER JP, ZYSSET F Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005; 40: 211-7.
16. NOVAKOVA Z Incidence of tuberculosis in the Czech Republic in 2009. Fast Information 2010 38/10. uzis.cz. accessed 21 Jul 2010. http://www.uzis.cz/en/fast-information/incidence-tuberculosis-czech-republic-2009.
17. LATORRE I, DE SOUZA-GALVÃO M, RUIZMANZANO J et al. Evaluating the non-tuberculous mycobacteria effect in the tuberculosis infection diagnosis. Eur Respir J 2010; 35: 338-42.
18. COMSTOCK GW How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-50.
19. HIGUCHI K, HARADA N, MORI T Interferongamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008; 13: 468-72.
20. DYRHOL-RIISE AM, GRAN G, WENTZELLARSEN T, BLOMBERG B, HAANSHUUS CG, MØRKVE O Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis 2010; 10: 57.
21. GOLETTI D, PARRACINO MP, BUTERA O et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 2007; 8: 5.
22. ESMAIL H, BARRY CE 3RD, WILKINSON RJ Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies, Drug Discov Today 2012; doi:10.1016/ j.drudis.2011.12.013.
23. AMITAL H, BARAK V, WINKLER RE, RUBINOW A Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. Ann N Y Acad Sci 2007; 1110: 649-60.
24. GIARDINA AR, ACCARDO-PALUMBO A, CICCIA F et al. Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vgamma9/Vdelta2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis? Reumatismo 2009; 61: 21-6.
25. AGNHOLT J, DAHLERUP JF, KALTOFT K The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 2003; 23: 76-85.
26. HAMDI H, MARIETTE X, GODOT V et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006; 8: R114.
27. POPA C, BARRERA P, JOOSTEN LA et al. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents. Eur Cytokine Netw 2009; 20: 88-93.
28. SALIU OY, SOFER C, STEIN DS, SCHWANDER SK, WALLIS RS Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006; 194: 486-92.
29. ARAVENA O, PESCE B, SOTO L et al. Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-γ-producing NK cell and regulatory T cell subsets. Immunobiology 2011; 216: 1256-63.
30. MISUMI M, HAGIWARA E, TAKENO M et al. Cytokine production profile in patients with Behçet's disease treated with infliximab. Cytokine 2003; 24: 210-8.